Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Calling for Nominations to the EDU Committee & its online subcommittee

November 7, 2023Education Committee (EDU)

Statement on Middle East

October 27, 2023

GEC announces the Competition-4-Ideas Winners

October 4, 2023Iranian Society of Immunology, Italian Society of Immunology, Clinical Immunology & Allergology and 3 more

Funding Opportunity from IUIS and FOCIS for Young Immunologists from the Developing World

September 27, 2023Federation of Clinical Immunology Societies, Gender Equality Committee (GEC)

Immuno-Mexico 2024: Mechanisms for Immunotherapies

September 26, 2023Sociedad Mexicana de Inmunologia, Latin American and Caribbean Association for Immunology and 1 more

2023 Day of Immunology Winners

September 8, 2023American Association of Immunologists (AAI), Sociedade Portuguesa de Imunologia and 3 more

Two fellowships available to attend the Spring School of the German Society for Immunology

September 5, 2023Education Committee (EDU)

ASI announces their new ASI Global Outreach Award

August 9, 2023Latin American and Caribbean Association for Immunology, Gender Equality Committee (GEC)

FIMSA Travel Awards for IUIS 2023 Congress

June 20, 2023Federation of Immunological Societies of Asia-Oceania (FIMSA)